Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.44 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.43 |
| ▸ | CCR2 | P41597 | 2/20 | 0.43 |
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
| ▸ | CCR1 | P32246 | 1/20 | 0.43 |
| ▸ | LMNA | P02545 | 1/20 | 0.43 |
| ▸ | GAA | P10253 | 1/20 | 0.43 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.43 |
| ▸ | F10 | P00742 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3143552 | 0.93 | F10 (0.49) | L3MBTL1KMT2ACCR2CCR1F10 | |
| SCHEMBL3145106 | 0.92 | F10 (0.49) | L3MBTL1ALDH1A1KMT2ACCR2CCR1 | |
| SCHEMBL3148378 | 0.92 | GAA (0.49) | L3MBTL1ALDH1A1HSD11B1KMT2ACCR2 | |
| SCHEMBL15103759 | 0.91 | GAA (0.44) | L3MBTL1ALDH1A1KMT2ACCR2MEN1 | |
| SCHEMBL3154679 | 0.90 | GAA (0.49) | L3MBTL1ALDH1A1HSD11B1KMT2ACCR2 | |
| SCHEMBL3148911 | 0.88 | ALDH1A1 (0.44) | L3MBTL1ALDH1A1KMT2ACCR2GAA | |
| SCHEMBL3148157 | 0.87 | GAA (0.46) | L3MBTL1ALDH1A1KMT2ACCR2GAA | |
| SCHEMBL3149703 | 0.87 | CCR2 (0.51) | L3MBTL1KMT2ACCR2CCR1 | |
| SCHEMBL3148887 | 0.86 | CCR2 (0.53) | L3MBTL1KMT2ACCR2CCR1 | |
| SCHEMBL15103804 | 0.85 | GAA (0.46) | ALDH1A1KMT2ACCR2MEN1CCR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2074083-B1 | NEW SULFONAMIDE DERIVATIVES AS BRADYKININ ANTAGONISTS | RICHTER GEDEON NYRT (HU) | 2013-06-19 | — | — | EP | disclosed |
| US-20100075978-A1 | SULFONAMIDE DERIVATIVES AS BRADYKININ ANTAGONISTS | RICHTER GEDEON NYRT. (HU) | 2010-03-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100075978-A1 | SULFONAMIDE DERIVATIVES AS BRADYKININ ANTAGONISTS | BDKRB1, BDKRB2, TRPV1 | L3MBTL1 3132/4885ALDH1A1 3552/4885HSD11B1 1594/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.